{"url_path":"/sec/supn/8-k/2026-07-22/item-2-02","section_key":"item-2-02","section_title":"Item 2.02 Results of Operations and Financial Condition.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-07-22","source_url":"https://www.sec.gov/Archives/edgar/data/1356576/0001356576-26-000031-index.html","accession_number":"0001356576-26-000031","cik":"0001356576","ticker":"SUPN","issuer_name":"SUPERNUS PHARMACEUTICALS, INC.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1356576/0001356576-26-000031-index.html","primary_entity_key":"0001356576","primary_entity_name":"SUPERNUS PHARMACEUTICALS, INC."},"word_count":88,"has_tables":true,"body_markdown":"Item 2.02 Results of Operations and Financial Condition.\n\nOn July 22, 2026, Supernus Pharmaceuticals, Inc. issued a press release announcing that it will report its business results for the second quarter of 2026 after the market closes on Tuesday, August 4, 2026. The Company will host a conference call and webcast on Tuesday, August 4, 2026 at 4:30 p.m. E.T. to discuss its second quarter 2026 financial and business results. A copy of this press release is furnished as Exhibit 99.1 hereto and is incorporated herein by reference."}